Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3,950.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 4,500.00
  • 52 Week Low: 3,800.00
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 8,977
  • Market Cap: £205.77m

Bioventix earnings surge thanks to sterling

By Josh White

Date: Monday 27 Mar 2017

LONDON (ShareCast) - (ShareCast News) - High-affinity antibody developer and supplier Bioventix announced its unaudited interim financial results for the six months to 31 December on Monday, with turnover rising 32% period-on-period to £3.12m.
The AIM-traded firm said profit before tax was up 49% at £2.48m, while profit after tax improved 41% to £1.98m.

Cash at period end was £0.54m higher than at the end of H2 2015, at £5.15m.

The board proposed an interim dividend of 20p per share, up 21% on the 16.5p declared in March 2016.

"As mentioned in our last report in October 2016, Bioventix revenues arriving in global currencies converted at post-Brexit referendum exchange rates give an uplift in reported sterling revenues of 15-20% as no hedging mechanisms are employed," commented chief executive officer Peter Harrison.

"The 2015/16 annual accounts featured such an effect for H1 2016 compared to H1 2015 and a similar effect accounts for some of the growth in the reporting period - H2 2016 compared to H2 2015."

Harrison said shipments to China had continued at a high frequency with the majority of antibodies being used for research and development purposes, and while revenues from China remained modest, the board was still optimistic that Bioventix antibodies were proving to be successful.

"We reported in October on the progress of our troponin partner Siemens Healthcare Diagnostics and a high sensitivity troponin test which features a Bioventix-created antibody.

"Whilst the exact timing of a Siemens product launch is confidential Siemens information and will be dependent on their discussions with global regulatory authorities, the board expects to hear news later in 2017 relating to their ex-US activities," Harrison explained on the subject of future developments.

"Significant troponin revenues during the financial year 2017/2018 are expected to offset the loss of revenues of around £800,000 from another product due to the expiry of the relevant agreement."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,950.00p
Change Today 50.00p
% Change 1.28 %
52 Week High 4,500.00
52 Week Low 3,800.00
Volume 8,977
Shares Issued 5.21m
Market Cap £205.77m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average
47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average
Income Not Available
Growth
78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average
2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 05-Aug-2021

Time Volume / Share Price
11:42 3,000 @ 3,851.00p
11:42 3,000 @ 3,850.00p
15:39 1,250 @ 3,880.00p
16:13 99 @ 3,925.00p
16:06 50 @ 3,920.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page